Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
NCT03283917Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2018
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab, ixazomib and dexamethasone in amyloid light chain amyloidosis, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Dose Limiting Toxicity Rate up to 28 days and Recommended Phase 2 Dose up to 24 months. Started Feb 2018; status: completed.
02
Drugs
daratumumabixazomibdexamethasone
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT03283917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283917.